0000950157-21-000841.txt : 20210813 0000950157-21-000841.hdr.sgml : 20210813 20210813164832 ACCESSION NUMBER: 0000950157-21-000841 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210601 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210813 DATE AS OF CHANGE: 20210813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERISOURCEBERGEN CORP CENTRAL INDEX KEY: 0001140859 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 233079390 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-16671 FILM NUMBER: 211173020 BUSINESS ADDRESS: STREET 1: 1 WEST FIRST AVENUE CITY: CONSHOHOCKEN STATE: PA ZIP: 19428 BUSINESS PHONE: 6107277000 MAIL ADDRESS: STREET 1: 1 WEST FIRST AVENUE CITY: CONSHOHOCKEN STATE: PA ZIP: 19428 8-K/A 1 form8k-a.htm CURRENT REPORT


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549



FORM 8-K/A



CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):  June 1, 2021


AmerisourceBergen Corporation
(Exact name of registrant as specified in its charter)


 
Delaware
 
1-16671
 
23-3079390
(State or other jurisdiction
 
(Commission
 
(I.R.S. Employer
of incorporation)
 
File Number)
 
Identification No.)
 
 
 
 
 
1 West First Avenue
Conshohocken, PA
 
 
 
 
19428-1800
(Address of principal executive offices)
 
 
 
(Zip Code)

Registrant’s telephone number, including area code:  (610) 727-7000
  
Not Applicable
____________________________________________
Former name or former address, if changed since last report
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of exchange on which registered
Common Stock
ABC
New York Stock Exchange (NYSE)
 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐



EXPLANATORY NOTE

On June 2, 2021, AmerisourceBergen Corporation (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) to report, among other things, its acquisition from Walgreens Boots Alliance, Inc. (“WBA”) of a majority of WBA’s Alliance Healthcare businesses (“Alliance Healthcare”), pursuant to a Share Purchase Agreement, dated January 6, 2021, by and between the Company and WBA.

This Current Report on Form 8-K/A (this “Amended 8-K”) amends and supplements the Original 8-K filed by the Company, and is being filed to provide the historical statements and the pro forma financial information required pursuant to Items 9.01(a) and 9.01(b) of Form 8-K, respectively.  In accordance with the requirements of Items 9.01(a)(3) and 9.01(b)(2) of Form 8-K, this Amended 8-K is being filed within 71 calendar days of the date that the Original 8-K was required to be filed with respect to the above referenced transaction.

Item 9.01 Financial Statements and Exhibits.

(a) Financial statements of business acquired.

The following audited financial statements of Alliance Healthcare are incorporated herein by reference to Exhibit 99.1 of the Company’s Current Report on Form 8-K filed on March 23, 2021.


Combined Balance Sheets as of August 31, 2020 and August 31, 2019;

Combined Statements of Equity for the years ended August 31, 2020 and August 31, 2019;

Combined Statements of Earnings for the years ended August 31, 2020 and August 31, 2019;

Combined Statements of Comprehensive Income for the years ended August 31, 2020 and August 31, 2019;

Combined Statements of Cash Flows for the years ended August 31, 2020 and August 31, 2019; and

Notes to Combined Financial Statements.
 
The following unaudited financial statements of Alliance Healthcare are filed as Exhibit 99.2 to this Amended 8-K and are incorporated herein by reference:
 

Unaudited Combined Condensed Balance Sheets as of May 31, 2021 and August 31, 2020;

Unaudited Combined Condensed Statements of Equity for the three and nine months ended May 31, 2021 and May 31, 2020;

Unaudited Combined Condensed Statements of Earnings for the three and nine months ended May 31, 2021 and May 31, 2020;

Unaudited Combined Condensed Statements of Comprehensive Income for the three and nine months ended May 31, 2021 and May 31, 2020;

Unaudited Combined Condensed Statements of Cash Flows for the nine months ended May 31, 2021 and May 31, 2020; and

Notes to Combined Condensed Financial Statements (Unaudited).

(b) Pro forma financial information.

The following unaudited condensed combined pro forma statement of operations combining the historical consolidated financial statements of the Company and Alliance Healthcare, reflecting the acquisition of Alliance Healthcare by the Company, are filed as Exhibit 99.3 to this Amended 8-K and are incorporated herein by reference:


Unaudited Condensed Combined Pro Forma Statement of Operations for the year ended September 30, 2020 and for the nine months ended June 30, 2021; and

Notes to Unaudited Condensed Combined Pro Forma Financial Statements.
 
No unaudited condensed combined pro forma balance sheet is required to be filed because the assets and liabilities of Alliance Healthcare are reflected on the Company’s consolidated balance sheet as of June 30, 2021 disclosed in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021.  The unaudited condensed combined pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of the assets acquired and the liabilities assumed of Alliance Healthcare based on management’s best estimates of fair value. The final purchase price allocation may vary based upon final appraisals, valuations, and analyses of the fair value of the assets acquired and assumed liabilities and is subject to change.  Accordingly, the pro forma adjustments are preliminary and have been made solely for illustrative purposes.  The unaudited condensed combined pro forma statement of operations for the year ended September 30, 2020 filed herewith reflects current assumptions as of the date hereof and supersedes the unaudited condensed combined pro forma statement of operations for the year ended September 30, 2020 included as Exhibit 99.3 of the Company’s Current Report on Form 8-K filed on March 23, 2021.


The pro forma financial information included in this Amended 8-K has been presented for informational purposes only. It does not purport to represent the actual results of operations that the Company and Alliance Healthcare would have achieved had the businesses been combined during the periods presented in the pro forma financial information and is not intended to project the future results of operations that the combined businesses may achieve.

Item 9.01. Financial Statements and Exhibits.

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
AmerisourceBergen Corporation
 
       
       
August 13, 2021
By:
/s/ James F. Cleary
 
   
Name:
James F. Cleary
 
   
Title: 
Executive Vice President and Chief Financial Officer
 
 

 
EX-99.2 2 ex99-2.htm UNAUDITED COMBINED CONDENSED FINANCIAL STATEMENTS

Exhibit 99.2

 
WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
UNAUDITED COMBINED CONDENSED BALANCE SHEETS
(in millions)

   
May 31, 2021
   
August 31, 2020
 
Assets
           
Current assets:
           
Cash and cash equivalents
 
$
239
   
$
143
 
Accounts receivable, net
   
3,524
     
3,022
 
Due from Parent (see note 10)
   
1,006
     
1,557
 
Inventories
   
1,669
     
1,535
 
Other current assets
   
410
     
376
 
Total current assets
   
6,847
     
6,633
 
Non-current assets:
               
Property, plant and equipment, net
   
572
     
546
 
Operating lease right-of-use asset
   
313
     
271
 
Goodwill
   
3,444
     
3,274
 
Intangible assets, net
   
650
     
681
 
Equity method investments
   
136
     
134
 
Other non-current assets
   
66
     
97
 
Total non-current assets
   
5,181
     
5,003
 
Total assets
 
$
12,028
   
$
11,636
 
                 
Liabilities and equity
               
Current liabilities:
               
Short-term debt
 
$
366
   
$
368
 
Due to Parent (see note 10)
   
76
     
60
 
Trade accounts payable
   
4,608
     
4,313
 
Operating lease obligation
   
82
     
68
 
Accrued expenses and other liabilities
   
677
     
679
 
Income taxes
   
(8
)
   
17
 
Total current liabilities
   
5,801
     
5,505
 
Non-current liabilities:
               
Operating lease obligation
   
238
     
209
 
Due to Parent (see note 10)
   
353
     
864
 
Deferred income taxes
   
139
     
131
 
Other non-current liabilities
   
70
     
73
 
Total non-current liabilities
   
800
     
1,277
 
Commitments and contingencies (see note 6)
               
                 
Equity:
               
Net Parent investment
   
6,217
     
5,814
 
Accumulated other comprehensive loss
   
(858
)
   
(1,022
)
Total equity attributable to the Business
   
5,359
     
4,792
 
Noncontrolling interests
   
68
     
62
 
Total equity
   
5,427
     
4,854
 
Total liabilities and equity
 
$
12,028
   
$
11,636
 

The accompanying notes to Combined Condensed Financial Statements are an integral part of these Statements.

-1-


WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
UNAUDITED COMBINED CONDENSED STATEMENTS OF EQUITY
FOR THE THREE AND NINE MONTHS ENDED MAY 31, 2021
 
(in millions)
 

Three months ended May 31, 2021
 
   
Equity attributable to the Business
             
                   
   
Net Parent
investment
   
Accumulated
other
comprehensive
income (loss)
   
Noncontrolling
Interests
   
Total
Equity
 
February 28, 2021
 
$
5,999
   
$
(855
)
 
$
66
   
$
5,210
 
Net earnings
   
52
     
-
     
2
     
54
 
Other comprehensive income (loss), net of tax
   
-
     
(3
)
   
-
     
(3
)
Adoption of new accounting standards
   
-
     
-
     
-
     
-
 
Net transfers to Parent
   
166
     
-
     
-
     
166
 
May 31, 2021
 
$
6,217
   
$
(858
)
 
$
68
   
$
5,427
 



Nine months ended May 31, 2021
 
    Equity attributable to the Business              
                         
   
Net Parent
investment
   
Accumulated
other
comprehensive
income (loss)
   
Noncontrolling
Interests
   
Total
Equity
 
August 31, 2020
 
$
5,814
   
$
(1,022
)
 
$
62
   
$
4,854
 
Net earnings
   
167
     
-
     
9
     
177
 
Other comprehensive income (loss), net of tax
   
-
     
164
     
-
     
164
 
Adoption of new accounting standards
   
(3
)
   
-
     
(3
)
   
(5
)
Net transfers to Parent
   
238
     
-
     
-
     
238
 
May 31, 2021
 
$
6,217
   
$
(858
)
 
$
68
   
$
5,427
 


-2-


WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
UNAUDITED COMBINED CONDENSED STATEMENTS OF EQUITY (Continued)
FOR THE THREE AND NINEX MONTHS ENDED MAY 31, 2020
 
(in millions)
 
 
Three months ended May 31, 2020
 
        Equity attributable to the Business              
                         
   
Net Parent
investment
   
Accumulated
other
comprehensive
income (loss)
   
Noncontrolling
interests
   
Total
Equity
 
February 29, 2020
 
$
5,904
   
$
(947
)
 
$
58
   
$
5,016
 
Net earnings
   
57
     
-
     
2
     
59
 
Other comprehensive income (loss), net of tax
   
-
     
(16
)
   
(1
)
   
(17
)
Dividends declared
   
-
     
-
                 
Net transfers to Parent
   
(106
)
   
-
     
-
     
(106
)
May 31, 2020
 
$
5,857
   
$
(963
)
 
$
58
   
$
4,953
 



Nine months ended May 31, 2020
 
  Equity attributable to the Business          
                 
 
Net Parent
investment
 
Accumulated
other
comprehensive
income (loss)
 
Noncontrolling
interests
 
Total
Equity
 
August 31, 2019
 
$
5,848
   
$
(1,333
)
 
$
58
   
$
4,573
 
Net earnings
   
177
     
-
     
7
     
184
 
Other comprehensive income (loss), net of tax
   
-
     
370
     
2
     
372
 
Dividends declared
   
-
     
-
     
(8
)
   
(8
)
Net transfers to Parent
   
(168
)
   
-
     
-
     
(168
)
May 31, 2020
 
$
5,857
   
$
(963
)
 
$
58
   
$
4,953
 

The accompanying notes to Combined Condensed Financial Statements are an integral part of these Statements.

-3-


WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
UNAUDITED COMBINED CONDENSED STATEMENTS OF EARNINGS
(in millions)

 
         Three months ended        Nine months ended
   
May 31,
2021
   
May 31,
2020
   
May 31,
2021
   
May 31,
2020
 
Sales
 
$
5,038
   
$
4,206
   
$
14,623
   
$
12,983
 
Related party sales (see Note 10)
   
462
     
444
     
1,367
     
1,364
 
Total Sales
   
5,500
     
4,650
     
15,990
     
14,347
 
Cost of sales
   
4,956
     
4,171
     
14,407
     
12,886
 
Gross profit
   
544
     
479
     
1,584
     
1,461
 
                                 
Selling, general and administrative expenses
   
460
     
389
     
1,325
     
1,196
 
Operating income
   
84
     
90
     
258
     
265
 
                                 
Other income (expense)
   
(1
)
   
(1
)
   
(2
)
   
(1
)
Earnings before interest and income tax provision
   
83
     
90
     
256
     
263
 
                                 
Interest expense, net
   
19
     
13
     
44
     
36
 
Earnings before income tax provision
   
64
     
76
     
212
     
228
 
                                 
Income tax provision
   
14
     
19
     
50
     
53
 
Post tax earnings from equity method investments
   
4
     
2
     
15
     
9
 
Net earnings
   
54
     
59
     
177
     
184
 
Net earnings attributable to noncontrolling interests
   
2
     
2
     
9
     
7
 
Net earnings attributable to the Business
 
$
52
   
$
57
   
$
167
   
$
177
 
 
The accompanying notes to Combined Condensed Financial Statements are an integral part of these Statements.
 
-4-


WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
UNAUDITED COMBINED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
(in millions)

 
   
Three months ended
 
Nine months ended
   
May 31,
2021
 
May 31,
2020
 
May 31,
2021
 
May 31,
2020
Comprehensive income:
                       
Net earnings
 
$
54
   
$
59
   
$
177
   
$
184
 
                                 
Other comprehensive income, net of tax:
                               
Currency translation adjustments
   
(3
)
   
(17
)
   
164
     
372
 
Total other comprehensive income
   
(3
)
   
(17
)
   
164
     
372
 
Total comprehensive income
   
51
     
42
     
341
     
556
 
                                 
Comprehensive income attributable to noncontrolling interests
   
2
     
1
     
9
     
9
 
Comprehensive income attributable to the Business
 
$
49
   
$
41
   
$
331
   
$
547
 

The accompanying notes to Combined Condensed Financial Statements are an integral part of these Statements.

-5-


WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
UNAUDITED COMBINED CONDENSED STATEMENTS OF CASH FLOWS
(in millions)
 
   
Nine months ended
Cash flows from operating activities:
 
May 31, 2021
 
May 31, 2020
Net earnings
 
$
177
   
$
184
 
Adjustments to reconcile net earnings to net cash provided by operating activities:
               
Depreciation and amortization
   
113
     
106
 
Deferred income taxes
   
(7
)
   
(10
)
Earnings from equity method investments
   
(15
)
   
(9
)
Other
   
10
     
13
 
Changes in operating assets and liabilities:
               
Accounts receivable, net
   
(518
)
   
(179
)
Inventories
   
(120
)
   
(316
)
Other current assets
   
(14
)
   
(17
)
Trade accounts payable
   
208
     
(6
)
Accrued expenses and other liabilities
   
(22
)
   
36
 
Income taxes
   
(14
)
   
15
 
Other non-current assets and liabilities
   
30
     
(7
)
Accounts receivable from Parent, net
   
(37
)
   
111
 
Net cash provided (used) for operating activities
   
(209
)
   
(81
)
                 
Cash flows from investing activities:
               
Additions to property, plant and equipment
   
(67
)
   
(45
)
Net change in cash pool receivable from Parent
   
751
     
(55
)
Net change in loan receivable from Parent
   
101
     
13
 
Other
   
9
     
3
 
Net cash provided (used) for investing activities
   
795
     
(84
)
                 
Cash flows from financing activities:
               
Net change in short-term debt with maturities of 3 months or less
   
11
     
53
 
Other
   
(16
)
   
(12
)
Net distribution to Parent
   
(513
)
   
(13
)
Net cash provided (used) for financing activities
   
(519
)
   
28
 
                 
Effect of exchange rate changes on cash, cash equivalents and restricted cash
   
3
     
(4
)
Changes in cash, cash equivalents and restricted cash
               
Net increase (decrease) in cash, cash equivalents, and restricted cash
   
71
     
(141
)
Cash, cash equivalents and restricted cash at beginning of period
   
311
     
319
 
Cash, cash equivalents and restricted cash at end of period
 
$
382
   
$
179
 

The accompanying notes to Combined Condensed Financial Statements are an integral part of these Statements.
 
-6-



WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
NOTES TO COMBINED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
 

Note 1. Organization, operations and basis of presentation
 
Organization
These Combined Condensed Financial Statements comprise certain pharmaceutical wholesale and retail pharmacy operations (the “Business”) of Walgreens Boots Alliance, Inc. (“WBA”).
 
Pharmaceutical wholesale operations comprise businesses located in the United Kingdom, France, Turkey, Spain, the Netherlands, Egypt, Norway, Romania, Czech Republic and Lithuania. Sales within these businesses are principally derived from wholesaling and distribution of a comprehensive offering of brand name and generic pharmaceuticals, health and beauty products, home healthcare supplies and equipment and related services to pharmacies, doctors, health centers and hospitals.
 
Retail pharmacy operations comprise retail stores in Norway, the Netherlands and Lithuania. Sales within these businesses are principally derived from pharmacy led sales of prescription drugs and health and wellness, beauty and personal care and other consumer products.
 
On January 6, 2021, WBA entered into a Share Purchase Agreement (the “Share Purchase Agreement”) with AmerisourceBergen Corporation (“the Transaction”). Pursuant to the terms and subject to the conditions set forth in the Share Purchase Agreement, AmerisourceBergen Corporation (“AmerisourceBergen”) agreed to purchase the Business for approximately $6.5 billion, comprised of $6.275 billion in cash, subject to certain purchase price adjustments, and 2 million shares of AmerisourceBergen common stock. On June 1, 2021 the Company completed the Transaction. See Note 13 Subsequent events.
 
Basis of presentation
The Business’s Combined Condensed Financial Statements have been prepared on a stand-alone basis and reflect a combination of entities and portions of certain entities under common control that have been “carved out” of and derived from the WBA historical consolidated financial statements and accounting records. Accordingly, WBA’s net investment in this Business (“Net Parent Investment”) is presented in lieu of a controlling interest’s equity in the Combined Condensed Financial Statements. Therefore, the Combined Condensed Financial Statements reflect the Business’s historical combined financial position, results of operations and cash flows as the Business was historically operated as part of WBA. As a result, the Business’s Combined Condensed Financial Statements may not be indicative of the Business’s future performance and do not necessarily reflect what the Business’s Combined Condensed results of operations, financial condition and cash flows would have been had the Business operated as a separate Business during the periods presented.
 
The Business is comprised of certain stand-alone legal entities for which discrete financial information is available, as well as portions of legal entities for which discrete financial information is not available (shared legal entities). For the shared legal entities for which discrete financial information was not available, allocation methodologies were applied to certain accounts to allocate amounts to the Business as discussed further in Note 10 – Related parties. The Combined Condensed Statements of Earnings include all sales and costs directly attributable to the Business, including costs for facilities, functions and services used by the Business. Certain shared costs and benefits have been directly charged to the Business based on direct usage or other allocation methods.
 
The Business participates in certain shared cash pool arrangements with WBA but retains a legal right to cash balances swept by WBA. WBA funds the Business’s operating and investing activities as needed. This arrangement is not reflective of the manner in which the Business would have been able to finance its operations had it been a stand-alone business separate from WBA during the periods presented. Cash pooling arrangements along with transfers to and from WBA’s cash management accounts are reflected in the Combined Condensed Balance Sheets as current amounts Due to and Due from Parent, and in the Combined Condensed Statements of Cash Flows as net investing activities. These Due to and Due from Parent balances are expected to be settled in the ordinary course of business.
 
The Combined Condensed Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The Business uses the equity method of accounting for equity investments in less than majority-owned companies if the investment provides the ability to exercise significant influence. All transactions between the entities comprising the Business have been eliminated. As described in Note 10 – Related parties, all significant transactions between the Business and WBA have been included in these Combined Condensed Financial Statements.
 
-7-


The combined operations of the Business are treated as if it was a separate taxpayer following the separate return methodology. See Note 7 – Income taxes.
 
The preparation of the Combined Condensed Financial Statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. These estimates are based on the information available at the time, historical experience and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of coronavirus COVID-19 (“COVID-19”). Significant estimates inherent in the preparation of these Combined Condensed Financial Statements include, but are not limited to, accounting for inventory, evaluation of goodwill and other assets for impairment, income taxes and other contingencies.
 
The impact of COVID-19 on the Business’s financial results depends on numerous evolving factors including, but not limited to, the severity and duration of COVID-19, and the potential impact to the customers, team members, suppliers, vendors, business partners, and distribution channels of the Business.
 
The Combined Condensed Financial Statements included herein are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Business believes that the disclosures are adequate to make the information presented not misleading. These unaudited Combined Condensed Financial Statements should be read in conjunction with the audited financial statements and the notes thereto for the fiscal year ended August 31, 2020. In the opinion of management, the unaudited Combined Condensed Financial Statements for the interim periods presented include all adjustments necessary to present a fair statement of the results for such interim periods.
 
Certain amounts in the Combined Condensed Financial Statements and associated notes may not foot due to rounding.
 
Note 2. Exit and disposal activities
 
Transformational Cost Management Program
On December 20, 2018, WBA announced a transformational cost management program that is currently expected to deliver in excess of $2 billion of annual cost savings by fiscal 2022 for WBA (the “Transformational Cost Management Program”). The Transformational Cost Management Program, which is multi-faceted and includes optimization initiatives, global smart spending, global smart organization and the transformation of the information technology (IT) capabilities, is designed to help WBA achieve increased cost efficiencies.
 
Since the inception of the Transformational Cost Management Program to May 31, 2021, the Business has recognized cumulative pre-tax charges to net income of $225 million, which were primarily recorded within selling, general and administrative expenses. These charges included $114 million in asset impairments and $110 million in employee severance, business transition and other exit costs.
 
Costs related to exit and disposal activities under the Transformational Cost Management Program, which were recorded in selling, general and administrative expenses in the fiscal years ended May 31, 2021 and May 31, 2020, are as follows (in millions):
 

   
Three months ended
 
   
May 31, 2021
   
May 31, 2020
 
Employee severance, business transition and other costs1
   
(9
)
   
3
 
Total pre-tax exit and disposal charges
 
$
(9
)
 
$
3
 

   
Nine months ended
 
   
May 31, 2021
   
May 31, 2020
 
Employee severance, business transition and other costs1
   
(4
)
   
12
 
Total pre-tax exit and disposal charges
 
$
(4
)
 
$
12
 

1 Includes $11 million reduction in accruals related to severance liabilities, initially estimated and accrued for in fiscal year 2020.
 
-8-


The changes in liabilities related to the exit and disposal activities under Transformational Cost Management Program include the following (in millions):
 
 
   
Employee
severance,
business
transition and
other costs
 
Balance at August 31, 2020
 
$
60
 
Remeasurement of severance liability
   
(4
)
Payments
   
(9
)
Balance at May 31, 2021
 
$
47
 
 
Note 3. Leases
 
The Business leases certain warehouses, distribution centers, office space, land, retail stores and equipment. Lease may include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Business becomes legally obligated to make rent payments or the date the Business has the right to control the property. The Business recognizes operating lease rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales.
 
Finance lease obligations as of May 31, 2021 and August 31, 2020 were $7 million and $10 million, respectively.
 
Supplemental balance sheet information related to operating leases were as follows (in millions):
 
   
May 31, 2021
 
August 31, 2020
Operating leases:
           
Operating lease right-of-use assets
 
$
313
   
$
271
 
                 
Operating lease obligations – current
   
82
     
68
 
Operating lease obligations – non-current
   
238
     
209
 
Total operating lease obligations
 
$
320
   
$
277
 
 
Supplemental income statement information related to operating leases were as follows (in millions):
 
   
Three months ended
   
Nine months ended
 
   
May 31, 2021
   
May 31, 2020
   
May 31, 2021
   
May 31, 2020
 
Operating lease cost
                       
Fixed
 
$
22
   
$
20
   
$
66
   
$
60
 
Variable 1
   
3
     
5
     
7
     
8
 

1
Includes real estate property taxes, common area maintenance and insurance
 
Other supplemental information was as follows (in millions):
 
   
Nine months ended
 
   
May 31, 2021
   
May 31, 2020
 
Cash paid for amounts included in the measurement of lease obligations:
           
Operating cash flows from operating leases
 
$
53
   
$
35
 
Right-of-use assets obtained in exchange for new lease obligations:
               
Operating leases
   
80
     
37
 
 
-9-


Average lease term and discount rate as of May 31, 2021 and August 31, 2020 were as follows (in millions):

Weighted average terms and discount rates:
 
May 31, 2021
   
August 31, 2020
 
Weighted average remaining lease term in years:
           
Operating leases
   
7.7
     
6.9
 
Weighted average discount rate:
               
Operating leases
   
3.38
%
   
3.42
%

The following table is a summary of the future minimum lease payments as of May 31, 2021 (in millions):
 
Future lease payments:

Fiscal year
 
Operating lease
 
2021(Remaining period)
 
$
26
 
2022
   
65
 
2023
   
51
 
2024
   
44
 
2025
   
37
 
2026
   
26
 
Later
   
98
 
Total undiscounted minimum lease payments
 
$
347
 
Less: Present value discount
   
(27
)
Lease liability
 
$
320
 


Note 4. Goodwill and other intangible assets
 
Goodwill and indefinite-lived intangible assets are evaluated for impairment annually during the fourth quarter or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit or intangible asset below its carrying value. Based on the annual impairment evaluation completed as of June 1, 2020 valuation date, the fair value of the Business’s reporting units exceeded the carrying amounts.
 
The determination of the fair value of the reporting units requires the Business to make significant estimates and assumptions including the business and financial performance of the Business’s reporting units, as well as how such performance may be impacted by COVID-19.
 
Although the Business believes its estimates of fair value are reasonable, actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. Changes in assumptions concerning future financial results or other underlying assumptions, including the impact of COVID-19, could have a significant impact on either the fair value of the reporting units and indefinite-lived intangibles, the amount of any goodwill and indefinite-lived intangible impairment charges, or both. These estimates can be affected by a number of factors including, but not limited to, the impact of COVID-19, its severity, duration and its impact on global economies, general economic conditions as well as our profitability. The Business will continue to monitor these potential impacts, including the impact of COVID-19 and economic, industry and market trends and the impact these may have on the Business.

Changes in the carrying amount of goodwill are presented below (in millions):
 
   
Carrying amount
of goodwill
 
August 31, 2020
 
$
3,274
 
Cumulative translation adjustments
   
170
 
May 31, 2021
 
$
3,444
 


-10-

 
The carrying amount and accumulated amortization of intangible assets consists of the following (in millions):

   
May 31, 2021
   
August 31, 2020
 
Gross amortizable intangible assets
           
Customer relationships
 
$
924
   
$
886
 
Trade names, trademarks and other
   
63
     
63
 
Total gross amortizable intangible assets
   
987
     
949
 
Accumulated amortization
               
Customer relationships
 
$
497
   
$
422
 
Trade names, trademarks and other
   
36
     
31
 
Total accumulated amortization
   
533
     
453
 
Total amortizable intangible assets, net
 
$
454
   
$
496
 
                 
Indefinite-lived intangible assets (Tradenames and Trademarks)
 
$
196
   
$
185
 
                 
Total intangible assets, net
 
$
650
   
$
681
 


Amortization expense for intangible assets was $21 million and $19 million for the three months ended May 31, 2021 and May 31, 2020, respectively. Amortization expense for intangible assets was $61 million and $57 million for the nine months ended May 31, 2021 and 2020, respectively. Estimated future annual amortization expense for the next five fiscal years for intangible assets recorded at May 31, 2021 is as follows (in millions):
 
   
2022
   
2023
   
2024
   
2025
   
2026
 
Estimated annual amortization expense
 
$
82
   
$
82
   
$
82
   
$
81
   
$
74
 


Note 5. Debt
 
Short-term debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. The carrying values of short-term debt approximated their respective fair values due to their short-term nature.
 
Interest paid on short-term debt was $33 million and $28 million for the nine months ended May 31, 2021 and May 31, 2020, respectively.
 
Note 6. Commitments and contingencies
 
The Business is involved in legal proceedings, including litigation, investigations, inspections, claims, inquiries and similar actions by pharmacy, healthcare, tax and other governmental authorities, arising in the normal course of the business. Legal proceedings, in general, can be expensive and disruptive. Some of these claims may purport to be or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Business is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters.
 
Like other companies in the retail pharmacy and pharmaceutical wholesale industries, the Business is subject to extensive regulation by national, state and local government agencies of countries in which it operates. There continues to be a heightened level of review and/or audit by regulatory authorities of, and increased litigation regarding, the Business’s and the rest of the health care and related industry’s business, compliance and reporting practices. As a result, the Business may regularly be the subject of government actions of the types described above.
 
-11-


The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome. The Business believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Business’s Combined Condensed financial position. However, substantial unanticipated judgments, fines and rulings do sometimes occur. As a result, the Business could from time to time incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid. In addition, as a result of governmental investigations or proceedings, the Business may be subject to damages, civil or criminal fines or penalties, or other sanctions, including the possible suspension or loss of licensure and/or suspension or exclusion from participation in government programs.
 
On July 25, 2019, the Competition and Markets Authority (“CMA”) issued a Statement of Objections against the Business which provisionally considers that the Business entered into arrangements to buy Nitrofurantoin from two suppliers and that these arrangements prevented or restricted competition. It is not a finding of infringement nor does it necessarily lead to an infringement decision. The Business takes UK competition law very seriously and does not believe that UK competition law has been infringed. The Business has reviewed the CMA’s provisional position, as specified in its Statement of Objections, and responded in detail to the allegations. The Business continues to defend its position whilst working constructively with the CMA. The CMA’s final decision on the case outcome is expected later in 2021 and it is possible that the CMA may impose a financial penalty on the Business if it determines that competition law has in fact been infringed. Any penalty will be determined in accordance with applicable provisions of competition law.
 
Gain contingencies, if any, are recognized when they are realized.
 
Note 7. Income taxes
 
The effective tax rate for the three months ended May 31, 2021 was 22.1%, primarily due to earnings in various jurisdictions taxed at different statutory tax rates. The effective tax rate for the three months ended May 31, 2020 was 24.5%, primarily due to earnings in various jurisdictions taxed at different statutory tax rates.
 
The effective tax rate for the nine months ended May 31, 2021 was 23.6%, primarily due to earnings in various jurisdictions taxed at different statutory tax rates. The effective tax rate for the nine months ended May 31, 2020 was 23.1%, primarily due to earnings in various jurisdictions taxed at different statutory tax rates.
 
Income taxes paid was $69 million and $77 million for the nine months ended May 31, 2021 and May 31, 2020, respectively.

On June 10, 2021 the UK Finance Act 2021 was enacted increasing the UK tax rate from 19% to 25% effective April 1, 2023.
 
Note 8. Retirement benefits
 
The Business sponsors several retirement plans, including defined benefit plans and defined contribution plans.
 
Defined benefit pension plans
 
The Business has unfunded defined benefit pension plans in Turkey and France. The total of net periodic pension cost for the three months ended May 31, 2021 and May 31, 2020 was $1 million and $1 million, respectively. The total of net periodic pension cost for the nine months ended May 31, 2021 and May 31, 2020 was $4 million and $3 million, respectively.
 
The Business plans to make $2 million of expected contributions for the whole year to its defined benefit pension plans in fiscal 2021.
 
Defined contribution plans
 
The Business has defined contribution arrangements for current employees. The largest scheme is the UK’s Alliance Healthcare Retirement Savings Plan, to which both the Business and participating employees contribute. The cost recognized in the Combined Condensed Statements of Earnings was $6 million and $5 million for the three months ended May 31, 2021 and May 31, 2020, respectively. The cost recognized in the Combined Condensed Statements of Earnings was $20 million and $18 million for the nine months ended May 31, 2021 and May 31, 2020, respectively.
 
-12-


Note 9. Accumulated other comprehensive income (loss)
 
The following is a summary of net changes in accumulated other comprehensive income by component, net of tax (in millions):
 
   
Pension/
post-
retirement
obligations
   
Cumulative
translation
adjustments
   
Total
 
Balance at February 28, 2021
 
$
(7
)
 
$
(848
)
 
$
(855
)
Other comprehensive income (loss)
   
-
     
(3
)
   
(3
)
Balance at May 31, 2021
 
$
(7
)
 
$
(851
)
 
$
(858
)

 
   
Pension/
post-
retirement
obligations
   
Cumulative
translation
adjustments
   
Total
 
Balance at August 31, 2020
 
$
(7
)
 
$
(1,015
)
 
$
(1,022
)
Other comprehensive income
   
-
     
164
     
164
 
Balance at May 31, 2021
 
$
(7
)
 
$
(851
)
 
$
(858
)

 
   
Pension/
post-
retirement
obligations
   
Cumulative
translation
adjustments
   
Total
 
Balance at February 29, 2020
 
$
(4
)
 
$
(943
)
 
$
(947
)
Other comprehensive income (loss)
   
-
     
(16
)
   
(16
)
Balance at May 31, 2020
 
$
(4
)
 
$
(959
)
 
$
(963
)

 
   
Pension/
post-
retirement
obligations
   
Cumulative
translation
adjustments
   
Total
 
Balance at August 31, 2019
 
$
(4
)
 
$
(1,329
)
 
$
(1,333
)
Other comprehensive income
   
-
     
370
     
370
 
Balance at May 31, 2020
 
$
(4
)
 
$
(959
)
 
$
(963
)

 
Note 10. Related parties
 
The Business, as part of its operations, has related party transactions and outstanding balances with Parent, WBA.
 
Corporate costs allocations
The Business’s Combined Condensed Financial Statements include allocation of corporate costs incurred by WBA, for services that are provided to or on behalf of the Business, using consistent and reasonable method based on gross profit metric. However, the expenses reflected in the Combined Condensed Financial Statements may not be indicative of the actual expenses that would have been incurred during the periods presented if the Business historically operated as a separate, stand-alone entity.
 
Allocated corporate costs included in Selling, general and administrative expense were for shared services and infrastructure provided, which includes costs such as information technology, accounting, legal, risk and insurance services, treasury, shareholder services and other corporate and infrastructure services. The Combined Condensed Statements of Earnings includes allocations of WBA’s general corporate costs of $6 million and $6 million for the three months ended May 31, 2021 and May 31, 2020, respectively. The Combined Condensed Statements of Earnings includes allocations of WBA’s general corporate costs of $17 million and $15 million for the nine months ended May 31, 2021 and May 31, 2020, respectively. All allocated corporate costs have been deemed paid by the Business to WBA in the period in which the cost was recognized in the Combined Condensed Statements of Income. These costs are included as cash outflow from the operating activities in the Combined Condensed Statements of cash flows.
 
-13-


Sales to and purchases from Parent
The sold products to WBA and the purchased products from WBA are as follows (in millions):
 
   
Three months ended
   
Nine months ended
 
   
May 31, 2021
   
May 31, 2020
   
May 31, 2021
   
May 31, 2020
 
Products sold to WBA
 
$
462
   
$
444
   
$
1,367
   
$
1,364
 
Products purchases from WBA
   
34
     
56
     
110
     
133
 
 
Related party balances
The amounts due to and from Parent, WBA and affiliates are as follows (in millions):
 
–Current assets
 
   
May 31, 2021
   
August 31, 2020
 
Trade accounts receivable
 
$
311
   
$
255
 
Debt due from Parent 1
   
695
     
1,302
 
Total due from Parent
 
$
1,006
   
$
1,557
 
 
–Current liabilities
 
   
May 31, 2021
   
August 31, 2020
 
Trade accounts payable
 
$
10
     
50
 
Debt due to Parent 2
   
66
     
8
 
Other
   
-
     
2
 
Total due to Parent
 
$
76
   
$
60
 

–Noncurrent liabilities

   
May 31, 2021
   
August 31, 2020
 
Due to Parent – Other
 
$
353
   
$
864
 

1
Debt due from Parent includes cash pool receivables from Parent classified as investing activities in the Combined Condensed Statements of Cash Flows.
2
Debt due to Parent includes interest bearing debt. Total interest expense payable to Parent, recognized in the Combined Condensed Statements of Earnings was $7 million and $7 million for the three months ended May 31, 2021 and May 31, 2020, respectively. Total interest expense payable to Parent, recognized in the Combined Condensed Statements of Earnings was $22 million and $20 million for the nine months ended May 31, 2021 and May 31, 2020, respectively.
 
See Note 13 Subsequent events for further information.
 
Note 11. New accounting pronouncements
 
Adoption of new accounting pronouncements
 
Financial Instruments
In March 2020, FASB issued ASU 2020-03. This ASU improves and clarifies various financial instruments topics. The ASU includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The Business adopted the new standard effective September 1, 2020 and the adoption did not have any impact on the Business’s results of operations, cash flows or financial position.
 
-14-


Investments - equity securities
In April 2019, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-04, Codification Improvements to Financial Instruments-Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 825). This extensive ASU provides clarifications for three topics related to financial instruments accounting, some of which apply to the Business. For example, this ASU clarifies the disclosure requirements that apply to equity securities without a readily determinable fair value for which the measurement alternative is elected. The Business adopted the new standard effective September 1, 2020 and the adoption did not have any impact on the Business’s results of operations, cash flows or financial position.
 
Compensation – retirement benefits – defined benefit plans
In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement benefits (Topic 715-20). This ASU amends ASC 715 to add, remove and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The ASU eliminates the requirement to disclose the amounts in accumulated other comprehensive income expected to be recognized as part of net periodic benefit cost over the next year. The ASU also removes the disclosure requirements for the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost and the benefit obligation for postretirement health care benefits. The Business adopted the new standard effective September 1, 2020 and the adoption did not have any impact on the Business’s results of operations, cash flows or financial position.
 
Financial instruments - credit losses
In June 2016, the FASB issued ASU 2016-13: Measurement of Credit Losses on Financial Instruments (Topic 326), which amends the Board’s guidance on the impairment of financial instruments. The ASU adds to U.S. GAAP an impairment model that is based on expected losses rather than incurred losses, which is known as the current expected credit loss (“CECL”) model. The CECL model applies to most debt instruments (other than those measured at fair value), trade and other receivables, financial guarantee contracts, and loan commitments. The Business adopted the new standard effective September 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment of $3 million to the opening balance of net parent investment to be recognized on the date of adoption with prior periods not restated. The adoption did not have a material impact on the Business’s financial position, cash flows or results of operations.
 
New accounting pronouncements not yet adopted
 
Codification Improvements – Disclosures
In October 2020, the FASB issued ASU 2020-10, Codification Improvements - Disclosures. This ASU improves consistency by amending the codification to include all disclosure guidance in the appropriate disclosure sections and clarifies application of various provisions in the Codification by amending and adding new headings, cross referencing to other guidance, and refining or correcting terminology. This ASU is effective for fiscal years beginning after December 15, 2020 (fiscal 2022). This ASU will not affect the Business’s results of operations, cash flows or financial position. The Business does not expect to have a material impact on the disclosures to the financial statements of the Business.
 
Effects of Reference Rate Reform on Financial Reporting
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional expedient and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. In response to the concerns about structural risks of interbank offered rates (“IBORs”) and, particularly, the risk of cessation of the London Interbank Offered Rate (“LIBOR”), regulators in several jurisdictions around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction based and less susceptible to manipulation. The ASU provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. In January 2021, the FASB issued ASU 2021-01, which adds implementation guidance to above ASU to clarify certain optional expedients in Topic 848. The ASUs can be adopted no later than December 1, 2022 with early adoption permitted. The Business is evaluating the effect of adopting this new accounting guidance.
 
Investments - equity securities; Investments—Equity Method and Joint Ventures; Derivatives and Hedging
In January 2020, the FASB issued ASU 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in this ASU clarify the interaction between the accounting for investments in equity securities, investment in equity method and certain derivatives instruments. The ASU is expected to reduce diversity in practice and increase comparability of the accounting for these interactions. This ASU is effective for fiscal years beginning after December 15, 2020 (fiscal 2022). The Business is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Business’s results of operations, cash flows or financial position.
 
-15-


Income taxes - simplifying the accounting for income taxes
In December 2019, the FASB issued ASU 2019-12: Simplifying the Accounting for Income Taxes (Topic 740), which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This ASU is effective for fiscal years beginning after December 15, 2020 (fiscal 2022), and interim periods within those fiscal years, with early adoption permitted. The Business is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Business’s disclosures.
 
Note 12. Supplemental Information
 
Accounts receivable
Accounts receivable are stated net of allowances for doubtful accounts. Accounts receivable balances primarily consist of trade receivables due from customers, clients and members. Trade receivables were $3.4 billion and $2.9 billion at May 31, 2021 and August 31, 2020, respectively. Other accounts receivable balances consist primarily of receivables from vendors and manufacturers. The carrying values of trade accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature.
 
In developing an estimate of the allowances for doubtful accounts, the Business considers historical information, current conditions and all reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The allowance for doubtful accounts for trade receivables at May 31, 2021 and August 31, 2020 was $39 million and $35 million, respectively.
 
Factoring arrangements
The Business entered into factoring agreements with various European financial institutions to sell accounts receivable under non-recourse agreements, transferring effective control and risk related to the receivables. These transactions are treated as a sale and were accounted for as a reduction in accounts receivable. The cost of factoring such accounts receivable, is reflected in the Combined Condensed Statement of Earnings within Selling, general and administrative expenses. The Business expects to continue to use this factoring arrangement periodically to assist with our general working capital requirements.
 
Depreciation and amortization
Depreciation and amortization expense for property, plant and equipment, including capitalized system development costs and software, was $39 million and $34 million for the three months ended May 31, 2021 and May 31, 2020, respectively. Depreciation and amortization expense for property, plant and equipment, including capitalized system development costs and software, was $113 million and $106 million for the nine months ended May 31, 2021 and May 31, 2020, respectively.
 
Accumulated depreciation and amortization on property, plant and equipment was $0.4 billion at May 31, 2021 and $0.3 billion at August 31, 2020.
 
Restricted cash
The Business is required to maintain certain cash deposits with banks mainly consisting of deposits restricted under contractual agency agreements and cash restricted by law and other obligations. The following represents a reconciliation of cash and cash equivalents in the Combined Condensed Balance Sheets to total cash, cash equivalents and restricted cash in the Combined Condensed Statements of Cash Flows as of May 31, 2021 and August 31, 2020 (in millions):
 
   
May 31, 2021
   
August 31, 2020
 
Cash and cash equivalents
 
$
239
   
$
143
 
Restricted cash (included in other current assets)
   
143
     
168
 
Cash, cash equivalents and restricted cash
 
$
382
   
$
311
 
 
Note 13. Subsequent events
 
On June 1, 2021, WBA completed the previously announced sale of Business, per the Share Purchase Agreement with AmerisourceBergen for a total consideration of $6.5 billion, made up of $6.275 billion in cash (subject to a customary net cash and working capital adjustment) and 2 million shares of AmerisourceBergen common stock.
 

-16-
EX-99.3 3 ex99-3.htm UNAUDITED CONDENSED COMBINED PRO FORMA FINANCIAL STATEMENTS
Exhibit 99.3

Unaudited Condensed Combined Pro Forma Statement of Operations
Fiscal Year Ended September 30, 2020
(in millions, except per share information)

   
AmerisourceBergen
   
Alliance Healthcare
   
Pro Forma Adjustments
   
Notes
 
Pro Forma Combined
 
Revenue
 
$
189,894
   
$
19,069
   
$
-
       
$
208,963
 
Cost of goods sold
   
184,702
     
17,130
     
-
         
201,832
 
Gross profit
   
5,192
     
1,939
     
-
         
7,131
 
Operating expenses:
           

                     
Distribution, selling, and administrative
   
2,767
     
1,479
     
-
         
4,246
 
Depreciation and amortization
   
391
     
141
     
157
   
 (b), (c)
   
689
 
Employee severance, litigation, and other
   
6,807
     
-
     
-
         
6,807
 
Impairment of PharMEDium assets
   
362
     
-
     
-
         
362
 
Operating (loss) income
   
(5,135
)
   
319
     
(157
)
       
(4,973
)
Other (income) loss
   
(2
)
   
2
     
(14
)
 
 (d)
   
(14
)
Interest expense, net
   
138
     
49
     
50
   
 (e)
   
237
 
Loss on early retirement of debt
   
22
     
-
     
-
         
22
 
(Loss) income before income taxes
   
(5,294
)
   
268
     
(193
)
       
(5,219
)
Income tax (benefit) expense
   
(1,894
)
   
71
     
(51
)
 
 (d), (f)
   
(1,874
)
Earnings from equity method investments, net of tax
   
-
     
10
     
(10
)
 
 (d)
   
-
 
Net (loss) income, including non-controlling interest
   
(3,400
)
   
207
     
(152
)
       
(3,345
)
Net (income) attributable to noncontrolling interest
   
(9
)
   
(9
)
   
-
         
(18
)
Net (loss) income attributable to the company
 
$
(3,409
)
 
$
198
   
$
(152
)
     
$
(3,363
)
                                     
Basic and diluted earnings per share
 
$
(16.65
)
                       
$
(16.27
)
                                     
Basic and diluted weighted common average shares outstanding
   
205
             
2
   
 (g)
   
207
 




Unaudited Condensed Combined Pro Forma Statement of Operations
Nine Months Ended June 30, 2021
(in millions, except per share information)

   
AmerisourceBergen
   
Alliance Healthcare
   
Pro Forma Adjustments
   
Notes
 
Pro Forma Combined
 
Revenue
 
$
155,076
   
$
15,990
   
$
(1,925
)
 
(a)
 
$
169,141
 
Cost of goods sold
   
150,203
     
14,407
     
(1,737
)
 
(a)
   
162,873
 
Gross profit
   
4,874
     
1,584
     
(187
)
       
6,271
 
Operating expenses:
                                   
Distribution, selling, and administrative
   
2,379
     
1,212
     
(134
)
 
(a)
   
3,457
 
Depreciation and amortization
   
327
     
113
     
88
   
 (a), (b), (h)
   
528
 
Employee severance, litigation, and other
   
376
     
-
     
(2
)
 
(a)
   
374
 
Operating income
   
1,792
     
258
     
(140
)
       
1,910
 
Other loss (income)
   
5
     
2
     
(20
)
 
 (i)
   
(13
)
Interest expense, net
   
119
     
44
     
21
   
 (a), (j)
   
184
 
Income before income taxes
   
1,668
     
212
     
(140
)
       
1,740
 
Income tax expense
   
560
     
50
     
(36
)
 
 (a), (i), (k)
   
574
 
Earnings from equity method investments, net of tax
   
-
     
15
     
(15
)
 
 (i)
   
-
 
Net income, including non-controlling interest
   
1,108
     
177
     
(119
)
       
1,166
 
Net (income) attributable to noncontrolling interest
   
(6
)
   
(9
)
   
-
         
(15
)
Net income attributable to the company
 
$
1,102
   
$
167
   
$
(119
)
     
$
1,151
 
                                     
Basic earnings per share
 
$
5.37
                         
$
5.56
 
Diluted earnings per share
 
$
5.31
                         
$
5.49
 
                                     
Basic weighted common average shares outstanding
   
205
             
1.8
   
 (l)
   
207
 
Diluted weighted common average shares outstanding
   
208
             
1.8
   
 (l)
   
209
 





Notes to Unaudited Condensed Combined Pro Forma Financial Information (in millions)

Note 1 - Acquisition and the basis of presentation

On June 1, 2021, the AmerisourceBergen Corporation (the “Company”) acquired a majority of Walgreens Boots Alliance, Inc.’s (“WBA”) Alliance Healthcare businesses (“Alliance Healthcare”) for $6,602.0 million in cash, subject to certain purchase price adjustments, $229.1 million of the Company’s common stock (2 million shares at the Company’s June 1, 2021 opening stock price of $114.54 per share), $118.2 million of estimated accrued consideration, and $6.1 million of other equity consideration (the “Transaction”). The net cash payment was $5,536.7 million, as the Company acquired $922.0 million of cash and cash equivalents and $143.3 million of restricted cash. The shares issued were from the Company’s treasury stock on a first-in, first-out basis and were originally purchased for $149.1 million. WBA’s operations in China, Italy, and Germany were not part of this Transaction. The Company funded the cash purchase price through a combination of cash on hand and new debt financing. The acquisition expands the Company’s reach and solutions in pharmaceutical distribution and adds to the Company’s depth and breadth of global manufacturer services.

The Company’s consolidated unaudited balance sheet as of June 30, 2021, as filed in its Form 10-Q, includes the preliminary allocation of the purchase price to the underlying assets acquired and liabilities assumed based upon their estimated fair values at the date of the acquisition.  The preliminary allocation is pending the finalization of the third-party appraisals of intangible assets and the corresponding deferred taxes, as well as the finalization of working capital account balances and the lease right-of-use assets and liabilities.  There can be no assurance that the estimated amounts recorded will represent the final purchase price allocation. 

The unaudited condensed combined pro forma financial statements are based on the Company’s and Alliance Healthcare’s historical financial statements as adjusted to give effect to the June 1, 2021 acquisition of Alliance Healthcare and the debt issuance necessary to finance a portion of the acquisition.  The Company’s historical results reflect its unaudited statement of operations for the nine months ended June 30, 2021 and audited statement of operations for the fiscal year ended September 30, 2020.  The Alliance Healthcare historical results reflect its unaudited statement of operations for the nine months ended May 31, 2021 and audited statement of operations for the fiscal year ended August 31, 2020.  Alliance Healthcare’s historical combined financial statements have been prepared on a stand-alone basis and reflect a combination of entities and portions of certain entities under common control that have been “carved-out” of and derived from WBA’s historical consolidated financial statements and accounting records.  As a result, the Alliance Healthcare historical financial statements may not necessarily reflect what its financial condition and results of operation would have been had Alliance Healthcare been an independent, stand-alone entity during the periods presented.  The unaudited condensed combined pro forma statements of operations for the nine months ended June 30, 2021 and the twelve months ended September 30, 2020 give effect to the Alliance Healthcare acquisition as if it had occurred on October 1, 2019.  The sum of the components of the unaudited condensed combined pro forma statements of operations may not equal the total due to rounding.  These unaudited condensed combined pro forma financial statements are presented for illustrative purposes only and do not necessarily reflect the operating results that would have occurred if the Alliance Healthcare acquisition had been consummated on the date indicated, nor is it necessarily indicative of the results of operations that may be expected for any future period or date.  Accordingly, such information should not be relied upon as an indicator of future performance.   

Based on a preliminary review of the accounting policies of the Company and Alliance Healthcare, the Company is not aware of any difference that would have a material impact on the unaudited condensed combined pro forma financial statements.   As more information becomes available, accounting policy differences may be identified and these differences, when identified, could have a material impact on the unaudited condensed combined pro forma financial statements.

Note 2 - Pro forma adjustments

Alliance Healthcare’s combined financial statements include allocation of corporate costs incurred by WBA, for services that are provided to or on behalf of Alliance Healthcare, using a consistent and reasonable method based on a gross profit metric.  The historical statements of operations for Alliance Healthcare reflect allocations of corporate costs from WBA for shared services and infrastructure provided, which includes costs such as information technology, accounting, legal, risk and insurance services, treasury, shareholder services and other corporate and infrastructure services.   The allocations may not, however, be indicative of the actual expenses that would have been incurred during the periods presented if Alliance Healthcare historically operated as a separate, stand-alone entity.




Following the Alliance Healthcare acquisition, certain functions such as information technology and infrastructure will be performed by the Company or third-party service providers.  For an interim period, however, some of these functions may continue to be provided by WBA under transition service agreements (“TSAs”).  Subsequent to the expiration of the TSAs, the costs for these services could be higher than those reflected in the historical financial statement of Alliance Healthcare.

The pro forma adjustments are based on our preliminary estimates and assumptions that are subject to change. The following adjustments have been reflected in the unaudited condensed combined pro forma financial information:

(a)
Reflects an adjustment to reverse the June 2021 operating results of Alliance Healthcare from the historical results of the Company, as there are already nine months of activity reflected in the historical Alliance Healthcare results.  See below detail:

Revenue
 
$
1,925
 
Cost of goods sold
   
1,737
 
Gross profit
   
187
 
Operating expenses:
       
Distribution, selling, and administrative
   
134
 
Depreciation and amortization
   
26
 
Employee severance, litigation, and other
   
2
 
Operating income
   
26
 
Other income
   
-
 
Interest expense, net
   
5
 
Income before income taxes
   
21
 
Income tax expense
   
4
 
Earnings from equity method investments, net of tax
   
-
 
Net income, including non-controlling interest
   
16
 
Net income attributable to noncontrolling interest
   
-
 
Net income attributable to the company
 
$
16
 

(b)
Reflects the adjustment of historical intangible assets acquired by the Company to their estimated fair values.  As part of the preliminary valuation analysis, the Company identified certain intangible assets, including trade names and customer relationships.


The following table summarizes the estimated fair value of Alliance Healthcare's identifiable intangible assets and their estimated useful lives and uses a straight line method of amortization:

   
Estimated
   
Weighted Average
Estimated Useful
   
Fiscal 2020
Amortization
   
Nine months ended
June 30, 2021
Amortization
 
   
Fair Value
   
Life in Years
   
Expense
   
Expense
 
Trade names
 
$
408
     
11.4
   
$
36
   
$
27
 
Customer relationships
   
3,327
     
17.8
     
187
     
140
 
   
$
3,735
             
223
     
167
 
                                 
Historical amortization expense
             
(77
)
   
(61
)
Pro forma adjustments
                 
$
146
   
$
106
 




These preliminary estimates of fair value and estimated useful lives could differ from the final amounts the Company will calculate after completing a detailed valuation analysis, and the difference could have a material effect on the accompanying unaudited condensed combined pro forma financial statements.  A 10% change in the valuation of intangible assets would cause a corresponding increase or decrease in the balance of goodwill and annual amortization expense of approximately $17 million, assuming an overall weighted-average useful life of 17.1 years.

(c)
Reflects $11 million of incremental depreciation expense related to the difference between the estimated fair value and the historical carrying value of PP&E.

(d)
Reclass $10 million of Alliance Healthcare’s historical Earnings from equity method investments, net of tax to Other (income) loss of $14 million of income and Income tax expense of $4 million in the condensed combined pro forma statements of operations.

(e)
Represents an increase of $50 million to reflect the incremental interest expense, including the amortization of debt issuance costs, based on a 1.464% weighted average interest rate, associated with the $2,525 million of fixed rate senior notes that were issued in March 2021 and $500 million of variable rate term debt that was issued in June 2021 to fund a portion of the acquisition of Alliance Healthcare.

(f)
Reflects the $55 million income tax effect of the pro forma adjustments based on the estimated statutory rate of 26.5%.

(g)
Represents an adjustment to the Company’s basic and diluted weighted average common shares outstanding to include an incremental two million shares that were issued in connection with the Alliance Healthcare acquisition.

(h)
Reflects $8 million of incremental depreciation expense related to the difference between the estimated fair value and the historical carrying value of PP&E.

(i)
Reclass $15 million of Alliance Healthcare’s historical Earnings from equity method investments, net of tax to Other loss (income) of $20 million of income and Income tax expense of $5 million in the condensed combined pro forma statements of operations.

(j)
Represents an increase of $26 million to reflect the incremental interest expense, including the amortization of debt issuance costs, based on a 1.464% weighted average interest rate, associated with the $2,525 million of fixed rate senior notes that were issued in March 2021 and $500 million of variable rate term debt that was issued in June 2021 to fund a portion of the acquisition of Alliance Healthcare.

(k)
Reflects the $37 million income tax effect of the pro forma adjustments based on the estimated statutory rate of 26.5%.

(l)
Represents an adjustment to the Company’s basic and diluted weighted average common shares outstanding to include an incremental two million shares that were issued in connection with the Alliance Healthcare acquisition, less 0.2 million shares that are already included in the Company’s historical weighted average common shares outstanding as a result of this share issuance.



EX-101.SCH 4 abc-20210601.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 abc-20210601_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 6 abc-20210601_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 form8k-a_htm.xml IDEA: XBRL DOCUMENT 0001140859 2021-06-01 2021-06-01 false 0001140859 8-K/A 2021-06-01 AmerisourceBergen Corporation DE 1-16671 23-3079390 1 West First Avenue Conshohocken PA 19428-1800 610 727-7000 Common Stock ABC NYSE false false false false false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Jun. 01, 2021
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag false
Document Period End Date Jun. 01, 2021
Entity Registrant Name AmerisourceBergen Corporation
Entity Incorporation, State or Country Code DE
Entity File Number 1-16671
Entity Tax Identification Number 23-3079390
Entity Address, Address Line One 1 West First Avenue
Entity Address, City or Town Conshohocken
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19428-1800
City Area Code 610
Local Phone Number 727-7000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001140859
Title of 12(b) Security Common Stock
Trading Symbol ABC
Security Exchange Name NYSE
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ^,'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " /A@U3".+''>\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>R$E&*2;-9:6G#08K;.QF;+4UB_]@:R1]^R5>FS*V!]C1TL^? M/H%:%83R$9^C#QC)8+H;;>^24&'#3D1! "1U0BM3.27+3I*4)45L&Z> M&,YCW\(-,,,(HTW?!=0+,5?_Q.8.L$MR3&9)#<-0#DW.33M4\/;T^)+7+8Q+ M))W"Z5&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" /A@U3C8:L32<$ \$ & 'AL+W=O_0L-5.Q-BRQ ^=H 90I*6[FZ6";29MM,+80NLB2U120[P M[WMDP&9;<\S>8,O6>?WH2'HE,=@J_69BSBW9I8DTPT9L[>:CYYDPYBDSMVK# M);Q9*9TR"T6]]LQ&:F"Q-F=[? M\T1MAPW:.#UX$>O8N@?>:+!A:S[G]K?-3$/)*U0BD7)IA))$\]6P,:8?[X.V M"\AK_"[XUIS=$]>4I5)OKC"-A@W?$?&$A]9),+B\\PE/$J<$'/\<11O%-UW@ M^?U)_2EO/#1FR0R?J.151#8>-GH-$O$5RQ+[HK:_\&.#[IQ>J!*3_Y+MH6Z[ MW2!A9JQ*C\% D IYN++=,1%G 2W_0D!P# AR[L.'"HBSHP<59I!D2YB,R*.TPN[)5!YZ&[(V\"Q\Q%7UPJ/@ M_4$PN"#X:R9OB4]O2. ']-MP#]@*P* #'*]U@6]B7KGFOPU7AJKH0O_1B1; MA60KEVS7M7FQW_"J%N+AO>8G;XQ@M N,-JHS!H8HYWA*V+J* X]?L<1PA..N MX+B[+ATSKH5RHR B,)8J,X,KY7U/;W[X\*&F\SL%6@<5/ [(%[X6KON!\9FE ME6"X#J1:"Z,R'?)[KM=P-F5O((E$:/I9) MJ_=PC2KA@3=KI=+%^[1G&_(9ZI&OLK(7 M:R0I>>4&YKK0\#M^YS+#)B\],W#Z7:@35X)!MU#;:OO&Y29*FEC%*GSCV,R@ MI7_3X+OXBEDQT^I=R+ ZE[CF#/-?6JX#%'?R_Z+-E+$L(7^*S<6I6J-(^^V@ MUZ0]'QV&Y0I!<8O/^W(,NZW+/+A AZ(@Y1)!<6?_K$)(S"Q6$K./&I%NT&UV M?3PUY" M)94\N$HM3VGY%/?KF>;-$-+#89(=]CNPX8#-U-?5ZD+_X7JU9*7]4]RM_T0L1WYQ*NA<"F8BY2V_=Y='R,[VZGCKKP0%G87:D5H\./R)S+G80:3 MM!H,5W*3&C8#"E9M M\N/A4EDX;.:W,1SON785X/U**7LJN!-G\8?!Z%]02P,$% @ #X8-4Y^@ M&_"Q @ X@P T !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8 MMD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2 M_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQD MB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G M8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E M#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-C MT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/C MO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,, MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@ M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$ M% @ #X8-4Y>*NQS $P( L !?3T\$MP>:4#M.*2V MBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YV MX$G1H2)8%II%R=.B':5_'FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X3[+O,&@EXN1:T/9=1,92L88!.R '<(Y_A^[<# MK3P&]'@!6^AC(,=D",Y1]XVXG\-/O4(VSV'T:$ M%'J6"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z M3XRQJK"$52Q;#X&'' E<)S"D&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V M<,TB]RI#FJ,,:&T'X:-:"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ : MC1W-CQ^W_ %02P,$% @ #X8-4R0>FZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C M,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI M160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=% MKLWC":[?#'!X=/X!4$L#!!0 ( ^-ED'F2&0$ ,\# 3 6T-O M;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^ MDV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT M(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W" MS&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE M8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F M"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D\ K @ $0 @ &O M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " /A@U3F5R<(Q & "<)P M$P @ '- 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 M ( ^.-AJQ-)P0 #P0 8 " @0X( !X;"]W;W)K M&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$" M% ,4 " /A@U399!YDAD! #/ P $P @ &!$@ 6T-O F;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #+$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://amerisourcebergen.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports form8k-a.htm abc-20210601.xsd abc-20210601_lab.xml abc-20210601_pre.xml ex99-2.htm ex99-3.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8k-a.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8k-a.htm" ] }, "labelLink": { "local": [ "abc-20210601_lab.xml" ] }, "presentationLink": { "local": [ "abc-20210601_pre.xml" ] }, "schema": { "local": [ "abc-20210601.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "abc", "nsuri": "http://amerisourcebergen.com/20210601", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "form8k-a.htm", "contextRef": "c20210601to20210601", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://amerisourcebergen.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "form8k-a.htm", "contextRef": "c20210601to20210601", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://amerisourcebergen.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0000950157-21-000841-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950157-21-000841-xbrl.zip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end